Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data

Citation:

Gagne JJ, Tsacogianis T, Bruce Wirta S, Rogers JR, Calado F, Chang C-L, Turner SJ, Schlienger RG, Balas B, Abdurrob A, et al. Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data. J Comp Eff Res. 2018;7 (11) :1073-1082.

Date Published:

2018 Nov

Abstract:

AIM: We examined characteristics of early sacubitril/valsartan users in a large US electronic health records database. PATIENTS & METHODS: We identified three cohorts of patients with heart failure (HF): sacubitril/valsartan patients with a prior HF diagnosis; patients with HF with reduced ejection fraction; and patients with HF treated with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker and a β-blocker. RESULTS: Sacubitril/valsartan patients were younger than patients in the other cohorts; the mean age of sacubitril/valsartan patients increased by 2 years in the first 15 months of marketing. Most sacubitril/valsartan patients had prior use of HF treatment. CONCLUSION: Overall, sacubitril/valsartan patients resembled those in the HF with reduced ejection fraction cohort, and commonly used other drugs for HF.